Tixagevimab |
| رقم الكتالوجGC72404 |
Tixagevimab (AZD8895) هو جسم مضاد بشري وحيد النسل يستهدف مجال ربط مستقبلات SARS-CoV-2 (RBD).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2420564-02-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tixagevimab can be combined with Cilgavimab to form AZD7442. AZD7442 (2, 4 or 16 mg/kg, i.v.) results in a dose-dependent decrease in lung infection titres and viral RNA levels and a significant reduction in infection titers at the 16 mg/kg dose compared to animals at the 2 mg/kg dose in hamsters infected with strain G614 or in hamsters infected with the Omicron variant[2].
References:
[1]. Jinhui Dong, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat Microbiol. 2021 Oct;6(10):1233-1244.
[2]. Jean-Sélim DRIOUICH, et al. Activity of Tixagevimab/Cilgavimab against the Omicron variant of SARS-CoV-2 in a hamster model.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *